An Open-label Phase II Study of BKM120 in Subjects With Relapsed and Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2018
At a glance
- Drugs Buparlisib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.
- 14 Sep 2017 Status changed from active, no longer recruiting to completed.
- 06 May 2017 This trial has been completed in Spain.
- 06 Mar 2017 Planned end date has changed from 1 Dec 2016 to 30 Jun 2017.